Loading clinical trials...
Loading clinical trials...
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Cellectis S.A.
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT07048535 · B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT07223021 · B-cell Acute Lymphoblastic Leukemia
NCT05674175 · B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California
University of Colorado - Aurora Cancer Center
Aurora, Colorado
Sarah Cannon - Colorado Blood Cancer Institute
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions